Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1414 studies found for:    "multiple sclerosis"
Show Display Options
Rank Status Study
21 Terminated
Has Results
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
Condition: Multiple Sclerosis
Intervention: Drug: BG9418 (interferon beta 1-a)
22 Recruiting Swiss Multiple Sclerosis Registry
Condition: Multiple Sclerosis
Intervention:
23 Completed
Has Results
A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: CNTO 1275
24 Recruiting Physical Telerehabilitation in Veterans With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Device: Multiple Sclerosis Home Automated Telemanagement (MS HAT) system
25 Not yet recruiting A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Biological: NeuroVax;   Biological: IFA Incomplete Freund's Adjuvant
26 Completed Yoga: Effect on Attention in Aging & Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Yoga
27 Completed A Pilot Study of Lithium in Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Lithium Carbonate
28 Unknown  MEsenchymal StEm Cells for Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Biological: Autologous Mesenchymal Stem Cells
29 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
30 Completed 12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: CS-0777 tablets
31 Completed
Has Results
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Interferon β-1a;   Drug: Teriflunomide
32 Recruiting Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Intervention:
33 Terminated A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: ELND002
34 Recruiting Pathological Basis of MRI Signal Changes in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
35 Recruiting Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Condition: Multiple Sclerosis
Interventions: Procedure: Hematopoietic Stem Cell Therapy;   Drug: Standard treatment with a conventional drug
36 Withdrawn Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
37 Active, not recruiting Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension
Condition: Multiple Sclerosis
Intervention: Other: Observational Cognitive assessments
38 Completed A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rituximab
39 Completed A Multi-center, Multi-regional Observational Study to Test the Responsiveness of the Validated MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire) Instrument to EDSS Status Changes in Any Form of Multiple Sclerosis (MS) in Patients With or Without Treatment
Condition: Multiple Sclerosis
Intervention:
40 Completed An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: rHIgM22

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.